Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

Clinical and Experimental Immunology

Volumn 135, Issue 2, 2004, Pages 286-293

  Pinder, M ^a   Reece, W H H ^c   Plebanski, M ^e   Akinwunmi, P ^a   Flanagan, K L ^c   Lee, E A M ^c   Doherty, T ^a   Milligan, P ^a   Jaye, A ^a   Tornieporth, N ^b   Ballou, R ^d   Mcadam, K P M J ^a   Cohen, J ^b   Hill, A V S ^c  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Cell mediated; Circumsporozoite; ELISPOT; Immunity; Plasmodium falciparum vaccine

Indexed keywords

ANTIGEN; CIRCUMSPOROZOITE PROTEIN; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; MALARIA VACCINE; PEPTIDE;

ADULT; AFRICA; AMINO ACID SEQUENCE; ARTICLE; BIOASSAY; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSPOT ASSAY; GAMBIA; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MALARIA; MALE; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE; VACCINATION;

ADOLESCENT; ADULT; ANTIGENS, PROTOZOAN; CELLS, CULTURED; COHORT STUDIES; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; GAMBIA; HEPATITIS B SURFACE ANTIGENS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PROTOZOAN PROTEINS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 10744225844     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2004.02371.x     Document Type: Article

References (21)

1. World Health Organization (WHO). State of the world's vaccines and immunisation. Who report. Geneva: WHO, 1996.
2. Kwiatkowski D, Marsh K. Development of a malaria vaccine. Lancet 1997; 350:1696-701.
3. Sinnis P, Nussenweig V. Preventing sporozoite invasion of hepatocytes. In: Hoffman SL, ed. Malaria vaccine development: a multi-immune response approach. Washington: ASM Press, 1996:15-34.
4. Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis 1995; 171:1576-85.
5. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 1997; 336:86-91.
6. Kester KE, McKinney DA, Tornieporth N et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J Infect Dis 2001; 183:640-7.
7. Stoute JA, Kester KE, Krzych U et al. Long-term efficacy and immune responses following immunisation with RTS,S malaria vaccine. J Infect Dis 1998; 178:1139-44.
8. Bojang KA, Milligan PJM, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001; 358:1927-34.
9. Doherty JF, Pinder M, Tornieporth N et al. A phase 1 safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. J Am J Trop Med Hyg 1999; 61:865-8.
10. Lindsay SW, Campbell H, Adiamah JH, Greenwood AM, Bangali JE, Greenwood BM. Malaria in a peri-urban area of The Gambia. Ann Trop Med Parasitol 1990; 84:553-62.
11. Whittle HC, Bradley AK, McLauchlan K et al. Hepatitis B virus infection in two Gambian villages. Lancet 1983; 1:1203-6.
12. Lalvani A, Moris P, Voss G et al. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum vaccine. J Infect Dis 1999; 180:1656-64.
13. Hoffman SL, Franke ED, Hollingdale MR, Druilhe P. Attacking the infected hepatocyte. In: Hoffman SL, ed. Malaria vaccine development: a multi-immune response approach. Washington: ASM Press, 1996:35-76.
14. Flanagan KL, Lee EA, Gravenor MB et al. Unique T cell effector functions elicited by Plasmodium falciparum epitopes in malaria-exposed Africans tested by three T cell assays. J Immunol 2001; 167:4729-37.
15. Jaye A, Magnusen AF, Whittle HC. Human leucocyte antigen class I-and class II-restricted cytotoxic T lymphocyte responses to measles antigens in immune adults. J Infect Dis 1998; 177:1282-9.
16. Bunce M, O'Neill CM, Barnardo MC et al. Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DBR4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995; 46:355-67.
17. Good MF, Pombo D, Quakyi IA et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci USA 1988; 85:1199-203.
18. Riley EM, Allen SJ, Bennett S et al. Recognition of dominant T cell-stimulating epitopes from the circumsporozoite protein of Plasmodium falciparum and relationship to malaria morbidity in Gambian children. Trans Roy Soc Trop Med Hyg 1990; 84:648-57.
19. Geginat J, Sallusto F, Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naïve, central memory and effector memory CD4 (+) T cells. J Exp Med 2001; 194:1711-9.
20. Elhassan IM, Hviid L, Satti G et al. Evidence of endothelial inflammation, T cell activation and T cell relocation in uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg 1994; 51:372-9.
21. Helmby H, Johnson G, Troye-Blomberg M. Cellular changes and apoptosis in the spleens and peripheral blood of mice infected with blood-stage Plasmodium chabaudi chabaudi AS. Infect Immun 2000; 68:1485-90.